DelSiTech is an innovative Finnish drug delivery technology company that helps its customers to turn their active agents into novel and commercially viable therapeutic drug products. DelSiTech offers one-stop shop opportunity in drug delivery up to early clinical proof of concept. The Company’s proprietary drug delivery technology is based on biodegradable silica (SiO2) matrix into which the active ingredient is embedded. The matrix can be designed to biodegrade at the required rate to assure a tightly controlled release of the active substance, providing a better therapeutic effect in situ and causing lower systemic and local adverse effects than alternative delivery systems. DelSiTech also develops its own supergeneric drug products to address significant unmet medical and commercial needs. The lead product, 1308 is a long-acting subcutaneous depot injection that offers for the first time a patient-friendly slow release treatment option to chronic hepatitis B infection.